Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Size, Trends, Growth Report 2033

Asia Pacific Type 1 Sbs If Short Bowel Syndrome With Intestinal Failure Treatment Market

Market Size in USD Million

CAGR : 8.00 %

Bar chart comparing the Asia Pacific Type 1 Sbs If Short Bowel Syndrome With Intestinal Failure Treatment Market size in 2025 - 210.71 and 2033 - 369.92, highlighting the projected market growth.

USD 210.71 Million USD 369.92 Million 2025 2033

Forecast Period	2026 - 2033
Market Size (Base Year)	USD 210.71 Million
Market Size (Forecast Year)	USD 369.92 Million
CAGR	8.00 %
Major Markets Players	Stanford Health Care (U.S.) HOSPIRA (Now part of Pfizer) (U.S.) Aurora Health Care (U.S.) Takeda Pharmaceutical Company Limited (Japan) Fresenius Kabi AG (Germany)

Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Overview

The Asia-Pacific type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market was valued at USD 210.71 Million in 2025 and is projected to reach USD 369.92 Million by 2033, growing at a CAGR of 8.0% from 2026 to 2033. The market is witnessing steady growth driven by the increasing prevalence of intestinal failure associated with major bowel resections, Crohn’s disease, mesenteric ischemia, trauma, congenital gastrointestinal disorders, and postoperative complications requiring intensive nutritional and pharmacological management.

The growing dependence on parenteral nutrition, advancements in GLP-2 analog therapies, increasing awareness regarding intestinal rehabilitation programs, and rising availability of home parenteral nutrition (HPN) services are significantly supporting market expansion. Additionally, improvements in multidisciplinary gastrointestinal care, pediatric SBS management, and personalized nutritional interventions are accelerating treatment adoption globally.

Key Market Trends & Insights

Japan is the dominating country in the Asia-Pacific Type 1 SBS-IF treatment market, accounting for the largest market share of 23.14% in 2025. This dominance is driven by the country’s advanced healthcare infrastructure, high diagnosis and treatment rates for rare gastrointestinal disorders, and strong adoption of innovative parenteral nutrition and biologic therapies.
Japan is also the fastest-growing country in the market, projected to expand at a CAGR of 9.0% during the forecast period from 2026–2033. This growth is fueled by rising awareness and early diagnosis of Short Bowel Syndrome–Intestinal Failure (SBS-IF), increasing demand for advanced nutritional therapies, and ongoing investments in rare disease management and innovative treatment development.
By treatment modality, nutritional support therapy dominated the Asia-Pacific type 1 SBS-IF treatment market, accounting for the largest market share of 42.51% in 2025, driven by the critical role of parenteral nutrition, enteral feeding, electrolyte management, and long-term nutritional rehabilitation in SBS-IF patient survival and recovery.
By treatment modality, emerging & advanced therapies is the fastest-growing segment in the market, projected to expand at a CAGR of 8.3% (2026–2033), supported by increasing adoption of GLP-2 analogs, intestinal growth factor therapies, regenerative medicine approaches, microbiome-based therapeutics, and novel intestinal rehabilitation technologies.
By market attribution, the core SBS-IF market dominated the market, holding a market share of 56.88% in 2025, driven by direct therapeutic interventions specifically targeting intestinal failure management and long-term nutritional dependency.
By market attribution, the SBS-IF attributable market is the fastest-growing segment, projected to expand at a CAGR of 8.3% (2026–2033), supported by increasing diagnosis rates, broader reimbursement coverage, and expanding supportive care services associated with SBS-related complications.
By disease management phase, the acute phase (type 1 SBS-IF) segment dominated the market, accounting for a market share of 48.43% in 2025, due to high hospitalization rates, intensive nutritional support requirements, and postoperative critical care management.
By disease management phase, the adaptation phase is the fastest-growing segment in the market, projected to expand at a CAGR of 8.2% (2026–2033), driven by increasing focus on intestinal rehabilitation, gradual reduction of parenteral dependence, and long-term recovery optimization strategies.

Market Size & Forecast

Global Market Value (2025): USD 210.71 Million
Expected Market Value (2033): USD 369.92 Million
Forecast CAGR (2026–2033): 8.0%
Leading Country in 2025: Japan
Fastest Growing Country: China

Report Scope and Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Segmentation

Attributes	Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Key Market Insights
Segments Covered	By Treatment Modality: Nutritional Support Therapy, Pharmacological Therapy, Surgical & Interventional Treatment, and Emerging & Advanced Therapies By Market Attribution: Core SBS-IF Market, SBS-IF Attributable Market, and Adjacent / Non-Specific Market By Disease Management Phase: Acute Phase (Type 1 SBS-IF), Adaptation Phase, and Recovery Phase By Patient Type: Adult and Pediatric By Route of Administration: Intravenous, Subcutaneous, Oral, and Enteral By End User: Hospitals (Acute Care), Home Care (HPN Programs), ICU Settings, Specialty GI Centers, and Pediatric Specialty Hospitals By Distribution Channel: Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy, and Online Pharmacy
Countries Covered	Asia-Pacific · Japan · China · South Korea · India · Singapore · Thailand · Indonesia · Malaysia · Philippines · Australia · New Zealand · Hong Kong · Taiwan · Rest of Asia-Pacific
Key Market Players	· Stanford Health Care (U.S.) · Hospira (U.S., now part of Pfizer) · Aurora Health Care (U.S.) · Takeda Pharmaceutical Company Limited (Japan) · Fresenius Kabi AG (Germany) · Grifols (Spain) · Abbott Laboratories (U.S.) · Shandong Qidu Pharmaceutical Co., Ltd. (China) · Ferring Pharmaceuticals (Switzerland) · UF Health (University of Florida Health) (U.S.) · Baxter International (U.S.) · VectivBio AG (Switzerland) · Ironwood Pharmaceuticals (U.S.) · Hikma Pharmaceuticals PLC (Jordan) · Nutricia (Netherlands) · Amsino International, Inc. (U.S.) · B. Braun Melsungen AG (Germany) · ContinuumRx (U.S.) · Jedux Parenteral Private Limited (India) · Beverly Hills Digestive Care (U.S.) · Choice Parenteral Nutrition LLC (U.S.) · Integrated Care Systems (U.S.) · Camvitaa (Not publicly verified) · Eclipse Regenesis (Not publicly verified) · Laboratoire Dielen (France) · Vision Parenteral Pvt. Ltd. (India) · Aculife Healthcare (India) · Nutrego (Not publicly verified) · Pharmko, Inc. (U.S.) · Infusion Solutions (U.S.) · NUTRICIA North America (U.S.) · Napo Therapeutics (Italy) · Moog Inc. (U.S.) · ICU Medical, Inc. (U.S.) · Puerto Life Sciences Pvt. Ltd (India) · Bausch Health Companies (Canada)
Market Opportunities	· Expansion of home parenteral nutrition (HPN) and outpatient intestinal rehabilitation programs · Rising adoption of GLP-2 analogs and advanced biologic therapies · Increasing development of personalized nutrition and regenerative intestinal therapies
Value Added Data Infosets	In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Trends

Trend: Growing Adoption of Intestinal Rehabilitation and GLP-2 Analog Therapies

The Type 1 SBS-IF treatment market is increasingly shifting toward comprehensive intestinal rehabilitation strategies that combine nutritional optimization, pharmacological therapy, and minimally invasive interventions. Advanced therapies such as GLP-2 analogs are gaining significant traction due to their ability to improve intestinal absorption, reduce dependence on parenteral nutrition, and enhance patient quality of life. Healthcare providers are also increasingly focusing on multidisciplinary care models integrating gastroenterologists, dietitians, surgeons, and home care specialists.

Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome With Intestinal Failure) Treatment Market Dynamics

Key Market Driver: Rising Prevalence of Intestinal Failure and Dependence on Parenteral Nutrition

The growing incidence of gastrointestinal resections, Crohn’s disease, ischemic bowel disease, congenital intestinal abnormalities, and postoperative complications is significantly increasing the prevalence of SBS-IF globally. Patients with severe intestinal insufficiency require long-term nutritional support, fluid management, and specialized therapies, driving strong demand for advanced SBS-IF treatment solutions and home parenteral nutrition programs.

Key Restraint/Challenge: High Treatment Costs and Long-Term Care Burden

One of the major challenges in the market is the high cost associated with long-term parenteral nutrition, biologic therapies, specialized nutritional formulations, and multidisciplinary care management. Additionally, patients undergoing prolonged treatment face risks of catheter-related infections, liver complications, metabolic imbalances, and reduced accessibility to specialized intestinal rehabilitation centers, particularly in developing regions.

Key Market Opportunity: Expansion of Home-Based Care and Advanced Biologic Therapies

The growing adoption of home healthcare services and portable infusion technologies is creating significant opportunities in the Type 1 SBS-IF treatment market. Increasing availability of home parenteral nutrition programs is improving patient convenience and reducing hospitalization costs. Furthermore, ongoing research in GLP-2 analogs, regenerative medicine, microbiome therapeutics, and tissue engineering is expected to accelerate innovation and improve long-term patient outcomes across the global SBS-IF treatment landscape.

Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Scope

The Asia-Pacific type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market is segmented on the basis of treatment modality, market attribution, disease management phase, patient type, route of administration, end user, and distribution channel.

By Treatment Modality

On the basis of treatment modality, the Asia-Pacific type 1 SBS-IF treatment market is segmented into nutritional support therapy, pharmacological therapy, surgical & interventional treatment, and emerging & advanced therapies. The nutritional support therapy segment dominated the market with a 42.51% share in 2025, driven by high dependence on parenteral nutrition (PN) and home parenteral nutrition (HPN) programs for managing severe malabsorption and long-term fluid-electrolyte imbalance in SBS-IF patients.

The emerging & advanced therapies segment is expected to witness the fastest growth at a CAGR of 8.3% from 2026 to 2033, supported by rising adoption of GLP-2 analogs, intestinal rehabilitation protocols, and regenerative medicine approaches aimed at reducing long-term PN dependency and improving intestinal adaptation outcomes across Japan, China, and Australia.

By Market Attribution

On the basis of market attribution, the Asia-Pacific type 1 SBS-IF treatment market is segmented into core SBS-IF market, SBS-IF attributable market, and adjacent/non-specific market. The core SBS-IF market segment dominated in 2025 with a 56.88% share, driven by direct clinical management of patients with confirmed intestinal failure requiring continuous nutritional and therapeutic support.

The SBS-IF attributable market segment is expected to witness moderate expansion at a CAGR of 8.3% from 2026 to 2033, supported by improved diagnostic accuracy, increasing identification of secondary intestinal failure cases, and expansion of specialized gastroenterology care networks in emerging Asia-Pacific economies.

By Disease Management Phase

On the basis of disease management phase, the market is segmented into acute phase (Type 1 SBS-IF), adaptation phase, and recovery phase. The acute phase segment dominated the market in 2025 with a 48.43% share, driven by critical care requirements including immediate stabilization, initiation of parenteral nutrition, and intensive monitoring in newly diagnosed patients.

The adaptation phase segment is expected to witness the fastest growth at a CAGR of 8.2% from 2026 to 2033, driven by increasing use of gut adaptation therapies, pharmacological interventions, and long-term nutritional optimization strategies to reduce PN dependency.

By Patient Type

On the basis of patient type, the Asia-Pacific Type 1 SBS-IF treatment market is segmented into adult and pediatric patients. The adult segment dominated the market in 2025 with a 71.50% share, primarily due to higher incidence following surgical resections caused by Crohn’s disease, ischemia, trauma, and post-operative complications.

The pediatric segment is expected to witness higher growth at a CAGR of 8.2% from 2026 to 2033, driven by rising congenital intestinal disorders such as necrotizing enterocolitis and intestinal atresia, along with improved survival rates in neonatal intensive care units.

By Route of Administration

On the basis of route of administration, the market is segmented into intravenous, subcutaneous, oral, and enteral routes. The intravenous segment dominated the market in 2025 with a 49.23% share, driven by extensive use of parenteral nutrition, IV fluid therapy, and intravenous drug administration in severe SBS-IF cases.

The subcutaneous segment is expected to witness the fastest growth at a CAGR of 8.3% from 2026 to 2033, supported by increasing adoption of injectable biologics such as GLP-2 analog therapies that enhance intestinal absorption and reduce dependence on intravenous nutrition.

By End User

On the basis of end user, the market is segmented into hospitals (acute care), home care (HPN programs), ICU settings, specialty GI centers, and pediatric specialty hospitals. The hospitals (acute care) segment dominated the market in 2025 with a 38.78% share, driven by high hospitalization rates for acute management, surgical complications, and initiation of long-term parenteral nutrition therapy.

The home care (HPN programs) segment is expected to witness the fastest growth at a CAGR of 8.6% from 2026 to 2033, supported by rising adoption of home-based care models, cost containment strategies, and improved infusion technologies enabling long-term outpatient management.

By Distribution Channel

On the basis of distribution channel, the Asia-Pacific Type 1 SBS-IF treatment market is segmented into hospital pharmacy, specialty pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market in 2025 with a 46.67% share, due to the critical requirement for sterile compounding, controlled dispensing, and inpatient administration of parenteral nutrition and specialized therapies.

The specialty pharmacy segment is expected to witness the fastest growth at a CAGR of 8.3% from 2026 to 2033, driven by increasing demand for biologics, customized nutrition formulations, and coordinated home infusion services.

Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Regional Analysis

Japan dominated the Asia-Pacific type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market, accounting for the largest revenue share of 23.14% in 2025, owing to its advanced healthcare infrastructure, high diagnosis rates, strong adoption of specialized therapies, and supportive reimbursement policies for rare gastrointestinal disorders.

Japan Type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment Market Insight

Japan dominates the Asia-Pacific Type 1 SBS-IF treatment market due to its advanced healthcare infrastructure, strong reimbursement framework, and widespread availability of specialized gastroenterology care. The country benefits from high diagnosis rates, early treatment intervention, and extensive adoption of advanced parenteral nutrition and supportive therapies for intestinal failure management. In addition, continuous investments in rare disease research, the presence of leading pharmaceutical companies, and increasing focus on long-term patient care contribute to sustained market growth and reinforce Japan’s leadership position in the regional market.

China Type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment Market Insight

China is witnessing significant growth in the Type 1 SBS-IF treatment market, driven by expanding healthcare infrastructure, rising healthcare expenditure, and increasing awareness of rare gastrointestinal disorders. Government initiatives supporting rare disease management, coupled with improving access to advanced medical facilities and nutritional support therapies, are enhancing treatment availability across the country. Furthermore, growing investments from pharmaceutical companies and ongoing improvements in diagnostic capabilities are expected to accelerate market expansion in the coming years.

South Korea Type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment Market Insight

South Korea’s Type 1 SBS-IF treatment market is supported by a highly developed healthcare system, strong government support for rare disease treatment, and rapid adoption of innovative medical technologies. The country’s emphasis on precision medicine, specialized gastrointestinal care, and advanced nutritional management solutions has improved treatment outcomes for SBS-IF patients. Continued investments in medical research and increasing availability of novel therapies are expected to further strengthen market growth and support the development of comprehensive patient care programs.

India Type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment Market Insight

India is emerging as a growing market for Type 1 SBS-IF treatment due to ongoing improvements in healthcare infrastructure, increasing awareness of intestinal disorders, and expanding access to specialty healthcare services. The growth of multispecialty hospitals, greater availability of clinical nutrition products, and rising healthcare spending are supporting the adoption of SBS-IF treatment solutions. Additionally, increasing focus on rare disease diagnosis and management, along with broader health insurance coverage, is expected to create new opportunities for market growth across the country.

Singapore Type 1 Sbs-If (Short Bowel Syndrome with Intestinal Failure) Treatment Market Insight

Singapore’s Type 1 SBS-IF treatment market is driven by its advanced healthcare system, strong emphasis on medical innovation, and growing demand for specialized rare disease therapies. The country’s well-established healthcare infrastructure, highly skilled medical professionals, and access to cutting-edge treatment options support effective management of intestinal failure conditions. As a regional healthcare hub, Singapore also benefits from ongoing clinical research activities, pharmaceutical investments, and increasing adoption of personalized treatment approaches, which continue to drive market development.

Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Share

The type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment industry is primarily led by well-established companies, including:

Stanford Health Care (U.S.)
Hospira (U.S., now part of Pfizer)
Aurora Health Care (U.S.)
Takeda Pharmaceutical Company Limited (Japan)
Fresenius Kabi AG (Germany)
Grifols (Spain)
Abbott Laboratories (U.S.)
Shandong Qidu Pharmaceutical Co., Ltd. (China)
Ferring Pharmaceuticals (Switzerland)
UF Health (University of Florida Health) (U.S.)
Baxter International (U.S.)
VectivBio AG (Switzerland)
Ironwood Pharmaceuticals (U.S.)
Hikma Pharmaceuticals PLC (Jordan)
Nutricia (Netherlands)
Amsino International, Inc. (U.S.)
Braun Melsungen AG (Germany)
ContinuumRx (U.S.)
Jedux Parenteral Private Limited (India)
Beverly Hills Digestive Care (U.S.)
Choice Parenteral Nutrition LLC (U.S.)
Integrated Care Systems (U.S.)
Camvitaa (Not publicly verified)
Eclipse Regenesis (Not publicly verified)
Laboratoire Dielen (France)
Vision Parenteral Pvt. Ltd. (India)
Aculife Healthcare (India)
Nutrego (Not publicly verified)
Pharmko, Inc. (U.S.)
Infusion Solutions (U.S.)
NUTRICIA North America (U.S.)
Napo Therapeutics (Italy)
Moog Inc. (U.S.)
ICU Medical, Inc. (U.S.)
Puerto Life Sciences Pvt. Ltd (India)
Bausch Health Companies (Canada)

Latest Developments in Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome With Intestinal Failure) Treatment Market

In January 2026, Fresenius Kabi has introduced a new dosage form of its biosimilar ustekinumab (Otulfi), offering a 45 mg/0.5 mL single-dose vial. This addition expands the available presentation range of Otulfi, which is a biosimilar to Janssen’s Stelara (ustekinumab). With this update, Fresenius Kabi now provides multiple dosage forms and strengths of the reference product, improving flexibility for physicians and treatment options for patients. This strengthens Fresenius Kabi’s biosimilar portfolio by improving product flexibility.
In March 2026, Baxter International has introduced the IV Verify Line Labeling System, an automated solution designed to replace handwritten IV labels with barcode-based, standardized labeling at hospitals. The system helps clinicians print clear, color-coded adhesive labels for IV tubing, improving accuracy and reducing medication errors at the bedside. It strengthens Baxter’s position in hospital infusion technology.
In February 2026, Nestlé Health Science announced the inclusion of its nutritional products under an exceptional reimbursement framework within Portugal’s public health system, allowing eligible products to be partially or fully covered by the National Health Service. This regulatory decision strengthens patient access to clinical nutrition solutions and supports integration of medical nutrition into formal healthcare reimbursement pathways. This will benefit the company by improving product accessibility, expanding prescription-based demand, and reinforcing its position within the reimbursed clinical nutrition market.
In 2025, Abbott expanded its Ensure and Glucerna nutrition product lines in 2025, introducing improved formulations with enhanced protein content, better taste, and additional product formats such as ready-to-drink shakes and snack-based nutrition options. The expansion is aimed at supporting muscle health, diabetes management, aging populations, and clinical nutrition needs in hospital and home-care settings.
In May 2024, Moog Inc. received FDA 510(k) clearance for its CURLIN 8000 Ambulatory Infusion System, a next-generation platform designed for advanced home infusion therapy. The system is engineered to deliver multiple therapies with improved precision, safety, and flexibility in ambulatory and home care settings. It enhances the accurate administration of drugs and nutrients, making it highly suitable for patients requiring long-term parenteral nutrition support. In the context of Short Bowel Syndrome with Intestinal Failure (SBS-IF), where patients often depend on home parenteral nutrition (HPN), the CURLIN 8000 plays an important supportive role.

SKU-76249

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 DBMR MARKET POSITION GRID

2.7 VENDOR SHARE ANALYSIS

2.8 MULTIVARIATE MODELING

2.9 PRODUCT TYPE TIMELINE CURVE

2.1 MARKET APPLICATION COVERAGE GRID

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.1.1 INTRODUCTION

4.1.2 POLITICAL ANALYSIS

4.1.3 ECONOMIC ANALYSIS

4.1.4 SOCIAL ANALYSIS

4.1.5 TECHNOLOGICAL ANALYSIS

4.1.6 ENVIRONMENTAL ANALYSIS

4.1.7 LEGAL ANALYSIS

4.1.8 CONCLUSION

4.2 PORTER’S FIVE FORCES ANALYSIS

4.2.1 INTRODUCTION

4.2.2 INTENSITY OF COMPETITIVE RIVALRY (HIGH)

4.2.3 BARGAINING POWER OF BUYERS – HIGH

4.2.4 THREAT OF NEW ENTRANTS – MODERATE

4.2.5 THREAT OF SUBSTITUTE PRODUCTS – MODERATE

4.2.6 BARGAINING POWER OF SUPPLIERS – MODERATE

4.2.7 CONCLUSION

4.3 COMPANY EVALUATION QUADRANT

4.4 PATIENT FUNNEL METHODOLOGY (MANDATORY MODEL)

4.4.1 A BOTTOM-UP PATIENT FUNNEL WILL BE CONSTRUCTED

4.4.1.1 TOTAL SBS POPULATION

4.4.1.2 SBS-IF POPULATION

4.4.1.3 DIAGNOSED SBS-IF PATIENTS

4.4.1.4 TREATED SBS-IF PATIENTS

4.4.1.5 THERAPY-SPECIFIC PATIENT POOLS

4.4.1.6 THIS ENSURES PATIENT NUMBERS ARE DIRECTLY ESTIMATED, NOT INFERRED FROM MARKET SIZE

4.4.1.7 ASIA-PACIFIC PATIENT FUNNEL SEGMENTATION

4.4.1.8 TOTAL SBS POPULATION

4.4.1.9 ADULT SBS

4.4.1.10 PEDIATRIC SBS

4.4.1.11 SBS-IF POPULATION

4.4.1.12 TYPE 1 SBS-IF (ACUTE)

4.4.1.13 TYPE 2 SBS-IF (PROLONGED ACUTE)

4.4.1.14 TYPE 3 SBS-IF (CHRONIC)

4.4.1.15 DIAGNOSED PATIENT POPULATION

4.4.1.16 DIAGNOSED – HOSPITAL-BASED

4.4.1.17 DIAGNOSED – OUTPATIENT FOLLOW-UP

4.4.1.18 UNDIAGNOSED / MISCLASSIFIED

4.4.1.19 TREATED PATIENT POPULATION

4.4.1.20 ACTIVELY TREATED PATIENTS

4.4.1.21 UNTREATED / SUPPORTIVE-ONLY

4.4.2 TREATMENT-SPECIFIC PATIENT SEGMENTATION (CRITICAL)

4.4.2.1 PN-DEPENDENT PATIENT POPULATION (CORE SEGMENT)

4.4.2.2 FULLY PN-DEPENDENT

4.4.2.3 PARTIALLY PN-DEPENDENT

4.4.2.4 ICU PN-DEPENDENT (TYPE 1 ACUTE)

4.4.2.5 HOME PN-DEPENDENT

4.4.2.6 GLP-2 ANALOGUE TREATED PATIENTS

4.4.2.7 INCLUDES PATIENTS RECEIVING TEDUGLUTIDE

4.4.2.8 PIPELINE THERAPIES (E.G., APRAGLUTIDE)

4.4.2.9 SUB-SEGMENTATION

4.4.2.10 PN-DEPENDENT RECEIVING GLP-2

4.4.2.11 PN-WEANING PATIENTS

4.4.2.12 PEDIATRIC VS ADULT

4.4.2.13 SUPPORTIVE PHARMACOTHERAPY PATIENTS (ATTRIBUTABLE)

4.4.2.14 ANTI-DIARRHEAL USERS

4.4.2.15 PPI USERS

4.4.2.16 ANTIBIOTIC (SIBO) PATIENTS

4.4.2.17 MICRONUTRIENT-DEPENDENT PATIENTS

4.4.2.18 SURGICAL & TRANSPLANT PATIENTS

4.4.2.19 INTESTINAL LENGTHENING PROCEDURES

4.4.2.20 TRANSPLANT PATIENTS

4.4.2.21 POST-TRANSPLANT SURVIVORS

4.4.3 PATIENT SEGMENTATION BY DEPENDENCY STATUS (HIGHLY IMPORTANT)

4.4.3.1 PN-DEPENDENT POPULATION

4.4.3.2 CORE REVENUE-DRIVING SEGMENT

4.4.3.3 PN-WEANING POPULATION

4.4.3.4 GLP-2 RESPONDERS

4.4.3.5 PN-INDEPENDENT POPULATION

4.4.3.6 MAINTAINED ON ORAL/ENTERAL THERAPY

4.4.4 PATIENT SEGMENTATION BY DISEASE PHASE (TYPE 1 FOCUS)

4.4.4.1 ACUTE PHASE (TYPE 1 SBS-IF)

4.4.4.2 ICU-MANAGED PATIENTS

4.4.4.3 HIGH PN UTILIZATION

4.4.4.4 ADAPTATION PHASE

4.4.4.5 TRANSITION TO ENTERAL NUTRITION

4.4.4.6 INITIATION OF GLP-2 THERAPY

4.4.4.7 RECOVERY / STABILIZATION PHASE

4.4.4.8 REDUCED PN DEPENDENCY

4.4.4.9 LONG-TERM MAINTENANCE

4.4.4.10 PATIENT SEGMENTATION BY CARE SETTING

4.4.4.11 HOSPITAL-BASED PATIENTS

4.4.4.12 ICU

4.4.4.13 SURGICAL WARDS

4.4.4.14 HOME CARE PATIENTS

4.4.4.15 HOME PARENTERAL NUTRITION (HPN)

4.4.4.16 SPECIALTY CENTERS

4.4.4.17 INTESTINAL REHABILITATION CENTERS

4.4.5 PATIENT SEGMENTATION BY DEMOGRAPHICS

4.4.5.1 AGE GROUP

4.4.5.2 NEONATES

4.4.5.3 PEDIATRIC

4.4.5.4 ADULTS

4.4.5.5 GERIATRIC

4.4.5.6 GENDER

4.4.5.7 MALE

4.4.5.8 FEMALE

4.4.6 PATIENT SEGMENTATION BY ETIOLOGY

4.4.6.1 ADULT ETIOLOGY

4.4.6.2 CROHN'S DISEASE

4.4.6.3 MESENTERIC ISCHEMIA

4.4.6.4 SURGICAL RESECTIONS

4.4.6.5 ONCOLOGY-RELATED

4.4.6.6 PEDIATRIC ETIOLOGY

4.4.6.7 NECROTIZING ENTEROCOLITIS (NEC)

4.4.6.8 CONGENITAL DEFECTS (ATRESIA, GASTROSCHISIS)

4.4.7 GEOGRAPHIC PATIENT DISTRIBUTION

4.4.7.1 NORTH AMERICA

4.4.7.2 U.S.

4.4.7.3 CANADA

4.4.7.4 EUROPE

4.4.7.5 GERMANY

4.4.7.6 FRANCE

4.4.7.7 UK

4.4.7.8 ITALY

4.4.7.9 SPAIN

4.4.7.10 ASIA-PAIFIC

4.4.7.11 JAPAN

4.4.7.12 CHINA

4.4.7.13 INDIA

4.4.8 TREATMENT PENETRATION & UTILIZATION RATES

4.4.8.1 PN PENETRATION RATE

4.4.8.2 % OF SBS-IF PATIENTS ON PN

4.4.8.3 GLP-2 PENETRATION RATE

4.4.8.4 % OF ELIGIBLE PATIENTS RECEIVING GLP-2

4.4.8.5 SUPPORTIVE THERAPY PENETRATION

4.4.8.6 ANTI-DIARRHEAL USAGE RATE

4.4.8.7 PPI USAGE RATE

4.4.8.8 PATIENT-LEVEL COST MODELING

4.4.8.9 ANNUAL COST PER PATIENT

4.4.8.10 PN COST (HOSPITAL VS HOME)

4.4.8.11 GLP-2 THERAPY COST

4.4.8.12 SUPPORTIVE THERAPY COST

4.4.9 COST BY PATIENT TYPE

4.4.9.1 PN-DEPENDENT

4.4.9.2 GLP-2 TREATED

4.4.9.3 TRANSPLANT

4.4.9.4 OUTPUT DELIVERABLES (EXCEL – CLIENT CRITICAL)

4.4.9.5 TOTAL SBS-IF PATIENTS (BY COUNTRY)

4.4.9.6 DIAGNOSED VS TREATED PATIENTS

4.4.9.7 PN-DEPENDENT PATIENTS

4.4.9.8 GLP-2 TREATED PATIENTS

4.4.9.9 TREATMENT PENETRATION RATES

4.4.9.10 AVERAGE ANNUAL COST PER THERAPY

4.5 INDUSTRY INSIGHTS

4.5.1 INTRODUCTION

4.5.2 INDUSTRY STRUCTURE OVERVIEW

4.5.3 MICRO AND MACRO ECONOMIC FACTORS

4.5.4 PENETRATION AND GROWTH PROSPECT MAPPING

4.5.5 KEY PRICING STRATEGIES

4.5.6 INTERVIEWS WITH SPECIALISTS

4.5.7 ANALYSIS AND RECOMMENDATION

4.5.8 CONCLUSION

4.6 WAR-DRIVEN DISRUPTION IN PHARMACEUTICAL SUPPLY CHAINS, GEOGRAPHIC FOOTPRINTS, STRUCTURAL CHANGES, AND ADAPTIVE STRATEGIES

4.6.1 INTRODUCTION

4.6.2 SUPPLY CHAIN RESILIENCE

4.6.2.1 DIVERSIFICATION OF INGREDIENT AND PN/DRUG SUPPLIERS

4.6.2.2 ESTABLISHMENT OF REGIONAL PRODUCTION HUBS

4.6.2.3 STRATEGIC STOCKPILING OF CRITICAL PN BAGS, GLP-2 ANALOGUES, AND MEDICAL DEVICES

4.6.2.4 DEVELOPMENT OF ALTERNATIVE LOGISTICS AND COLD CHAIN ROUTES

4.6.2.5 STRATEGIC PARTNERSHIPS WITH LEADING CDMOS (E.G., CATALENT, LONZA)

4.6.2.6 EXPANSION OF MANUFACTURING, FILL-FINISH, AND PACKAGING CAPABILITIES FOR PN & GLP-2

4.6.3 ENERGY & MANUFACTURING OPERATIONAL COST RISK

4.6.3.1 RISING ENERGY COSTS IN PARENTERAL NUTRITION & DRUG FACILITIES

4.6.3.2 INCREASED COSTS FOR RAW MATERIALS, LIPID EMULSIONS, AND PHARMACEUTICALS

4.6.3.3 LONG-TERM ENERGY PROCUREMENT STRATEGIES FOR PN MANUFACTURERS

4.6.3.4 ADOPTION OF ENERGY-EFFICIENT MANUFACTURING TECHNOLOGIES

4.6.3.5 DEPLOYMENT OF ADVANCED AUTOMATION AND CONTINUOUS SYSTEMS

4.6.3.6 INTEGRATION OF RENEWABLE ENERGY IN MANUFACTURING FACILITIES

4.6.4 GEOGRAPHIC FOOTPRINT REASSESSMENT

4.6.4.1 EXPANSION OF MANUFACTURING IN STABLE REGIONS

4.6.4.2 DIVERSIFICATION OF ASIA-PACIFIC PN/GLP-2 PRODUCTION SITES

4.6.4.3 RELOCATION OF KEY INPUT/INTERMEDIATE PRODUCTION

4.6.4.4 EXPANSION INTO EMERGING MARKETS WITH HIGH SBS-IF BURDEN

4.6.4.5 ESTABLISHMENT OF REGIONAL COLD CHAIN TRANSIT AND DISTRIBUTION HUBS

4.6.5 SCENARIO PLANNING & RISK MANAGEMENT

4.6.5.1 DEVELOPMENT OF SUPPLY CHAIN CONTINGENCY PLANS

4.6.5.2 MULTI-SOURCE PROCUREMENT STRATEGIES FOR PN/GLP-2

4.6.5.3 GOVERNMENT AND HEALTH AUTHORITY COLLABORATIONS

4.6.5.4 CRISIS-RESPONSE SUPPLY NETWORKS FOR CRITICAL THERAPIES

4.6.5.5 DEPLOYMENT OF PREDICTIVE SUPPLY CHAIN ANALYTICS IN SBS-IF MARKET

4.6.6 CASH & FINANCIAL PROTECTION

4.6.7 STRENGTHENING CAPITAL RESERVES FOR PN & BIOPHARMA EXPANSION

4.6.7.1 DIVERSIFICATION OF PRODUCT PORTFOLIOS AND REVENUE STREAMS

4.6.7.2 INVESTMENTS IN DOMESTIC PRODUCTION INFRASTRUCTURE

4.6.7.3 GOVERNMENT INCENTIVES AND PUBLIC-PRIVATE PARTNERSHIPS

4.6.7.4 LONG-TERM PROCUREMENT CONTRACTS WITH HEALTHCARE SYSTEMS

4.6.8 DATA PROTECTION

4.6.8.1 DATA PROTECTION FRAMEWORKS FOR CLINICAL AND REAL-WORLD SBS-IF DATA

4.6.8.2 PROTECTION OF CLINICAL TRIAL DATA, PATIENT DATA, AND DRUG DEVELOPMENT

4.6.8.3 SECURE CLOUD INFRASTRUCTURE FOR SBS-IF DATA MANAGEMENT

4.6.8.4 AI-DRIVEN THREAT DETECTION IN MARKET RESEARCH AND PHARMA NETWORKS

4.6.8.5 COMPLIANCE WITH PHARMACEUTICAL DATA REGULATIONS & GXP

4.6.9 NEW BUSINESS AND EMERGING REVENUE OPPORTUNITIES & FUTURE OUTLOOK

4.6.10 CONCLUSION

4.7 EPIDEMIOLOGY

4.7.1 INTRODUCTION

4.7.2 INCIDENCE OF TYPE 1 SBS-IF BY GENDER

4.7.3 TREATMENT RATE

4.7.4 MORTALITY RATE

4.7.5 TREATMENT ADHERENCE AND SWITCH MODEL

4.7.6 PATIENT TREATMENT SUCCESS RATES

4.7.7 CONCLUSION

4.8 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE ASIA-PACIFIC TYPE 1 SBS-IF MARKET

4.9 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE – ASIA-PACIFIC TYPE 1 SBS-IF MARKET

4.1 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE – ASIA-PACIFIC TYPE 1 SBS-IF MARKET

4.11 PIPELINE ANALYSIS

4.11.1 INTRODUCTION

4.11.2 CLINICAL TRIALS AND PHASE ANALYSIS

4.11.3 DRUG & BIOTHERAPY PIPELINE

4.11.4 PHASE III CANDIDATES (E.G., APRAGLUTIDE)

4.11.5 PHASE II CANDIDATES (E.G., LONG-ACTING GLP-2)

4.11.6 PHASE I CANDIDATES (EMERGING REGENERATIVE/CELLULAR)

4.11.7 OTHERS (PRE-CLINICAL, EN FORMULATION PIPELINE)

4.11.8 CONCLUSION

4.12 PIPELINE ANALYSIS

4.12.1 INTRODUCTION

4.12.2 TAKEDA PHARMACEUTICAL COMPANY – R&D LEADERSHIP IN INTESTINAL REGENERATION THERAPIES

4.12.3 BAXTER INTERNATIONAL – PARENTERAL NUTRITION AND INFUSION SYSTEM INNOVATION

4.12.4 FRESENIUS KABI AG – CLINICAL NUTRITION AND INJECTABLE THERAPY DEVELOPMENT

4.12.5 NESTLÉ HEALTH SCIENCE – MEDICAL NUTRITION AND GUT ADAPTATION RESEARCH

4.12.6 ABBOTT LABORATORIES – INTEGRATED NUTRITION AND METABOLIC MONITORING SOLUTIONS

4.12.7 CONCLUSION

4.13 MARKETED THERAPY ANALYSIS

4.13.1 INTRODUCTION

4.13.2 DRUG/THERAPY

4.13.2.1 BRAND NAME

4.13.2.2 GENERICS NAME

4.13.3 PHARMACOLOGICAL CLASSIFICATION

4.13.4 PRIMARY INDICATION

4.13.5 MARKET STATUS

4.13.6 MEDICATION TYPE

4.13.7 DOSAGE FORM

4.13.8 DOSAGE AVAILABILITY

4.13.9 PACKAGING TYPE

4.13.10 ROUTE OF ADMINISTRATION

4.13.11 DOSING FREQUENCY

4.13.12 THERAPY INSIGHT

4.13.13 AN OVERVIEW OF DRUG DEVELOPMENT ACTIVITIES, REGULATORY MILESTONES, SAFETY/EFFICACY, MARKET EXCLUSIVITY DATA

4.13.14 FORECAST MARKET OUTLOOK

4.13.14.1 CROSS COMPETITION

4.13.14.2 THERAPEUTIC PORTFOLIO

4.13.14.3 CURRENT DEVELOPMENT SCENARIO

4.13.15 CONCLUSION

4.14 PIPELINE ANALYSIS - ASIA-PACIFIC TYPE 1 SBS-IF TREATMENT MARKET

4.14.1 CLINICAL TRIALS AND PHASE ANALYSIS

4.14.2 DRUG AND BIOTHERAPY PIPELINE

4.14.3 PHASE III CANDIDATES

4.14.4 PHASE II CANDIDATES

4.14.5 PHASE I CANDIDATES

4.14.6 OTHERS (PRE-CLINICAL AND RESEARCH STAGE)

4.15 R & D ANALYSIS

4.15.1 COMPARATIVE ANALYSIS

4.15.2 DEVELOPMENTAL LANDSCAPE

4.15.3 INSIGHTS ON REGULATORY MILESTONES

4.15.4 THERAPEUTIC ASSESSMENT

4.15.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS

5 HEALTHCARE TARIFFS IMPACT ANALYSIS

5.1 OVERVIEW

5.2 TARIFF STRUCTURES

5.2.1 ASIA-PACIFIC VS. REGIONAL TARIFF STRUCTURES

5.2.2 UNITED STATES: MEDICARE/MEDICAID TARIFF POLICIES

5.2.3 ASIA-PACIFIC: GOVERNMENT TARIFFS ON IMPORTED PN/DRUG THERAPIES

5.2.4 EMERGING MARKETS: TARIFF CHALLENGES FOR NUTRITION & BIOLOGICS

5.2.5 MAJOR MARKET UPTAKE

5.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS

5.3.1 IMPORT DUTIES ON PN KITS, GLP-2 VS. GENERICS

5.3.2 IMPACT ON AFFORDABILITY & ACCESS

5.3.3 KEY TRADE AGREEMENTS AFFECTING SBS-IF PRODUCTS

5.4 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS/PATIENTS

5.4.1 COST BURDEN ON HOSPITALS AND FACILITIES

5.4.2 EFFECT ON PATIENT AFFORDABILITY & INSURANCE COVERAGE

5.4.3 ROLE IN MEDICAL TOURISM FOR ADVANCED SBS-IF THERAPIES

5.5 TRADE AGREEMENTS AND HEALTHCARE TARIFFS

5.5.1 WTO REGULATIONS

5.5.2 TRADE WARS IMPACT ON SUPPLY CHAIN

5.5.3 FTAS IN REDUCING TARIFFS

5.6 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY

5.7 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR

6 MARKET ACCESS

6.1 10-YEAR MARKET FORECAST

6.2 CLINICAL TRIAL RECENT UPDATES

6.3 ANNUAL NEW FDA APPROVALS FOR SBS-IF TREATMENTS

6.4 MANUFACTURERS, DISTRIBUTORS, AND DEALS

6.5 MAJOR MARKET UPTAKE

6.6 CURRENT TREATMENT PRACTICES

6.7 IMPACT OF UPCOMING THERAPIES

7 REGULATORY FRAMEWORK–

7.1 INTRODUCTION

7.2 REGULATORY APPROVAL PROCESS

7.3 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL

7.4 REGULATORY APPROVAL PATHWAYS

7.5 LICENSING AND REGISTRATION

7.6 POST-MARKETING SURVEILLANCE

7.7 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES

7.8 CONCLUSION

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 RISING SBS-IF PATIENT POPULATION

8.1.2 GROWING ADOPTION OF GLP-2 THERAPIES

8.1.3 INCREASING GOVERNMENT & ORPHAN DRUG SUPPORT

8.2 RESTRAINTS

8.2.1 HIGH COST OF SBS-IF TREATMENT

8.2.2 LIMITE.D AWARENESS & DELAYED DIAGNOSIS

8.3 OPPORTUNITIES

8.3.1 COMPLEX MULTIDISCIPLINARY PATIENT MANAGEMENT

8.3.2 STRINGENT REGULATORY APPROVAL PROCESSES

8.4 CHALLENGES

8.4.1 ADVANCEMENTS IN REGENERATIVE MEDICINE

8.4.2 EXPANSION OF HOME-BASED NUTRITIONAL CARE

9 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY

9.1 OVERVIEW

9.2 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

9.2.1 NUTRITIONAL SUPPORT THERAPY

9.2.2 PHARMACOLOGICAL THERAPY

9.2.3 SURGICAL & INTERVENTIONAL TREATMENT

9.2.4 EMERGING & ADVANCED THERAPIES

9.3 ASIA-PACIFIC NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.3.1 PARENTERAL NUTRITION (PN)

9.3.2 ENTERAL NUTRITION (EN)

9.3.3 PN COMPOSITION

9.4 ASIA-PACIFIC PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.4.1 HOME PARENTERAL NUTRITION (HPN)

9.4.2 PERIPHERAL PARENTERAL NUTRITION (PPN)

9.4.3 CYCLIC PARENTERAL NUTRITION

9.5 ASIA-PACIFIC TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.5.1 HOSPITAL-BASED TPN

9.5.2 ICU-BASED TPN

9.6 ASIA-PACIFIC HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

9.6.1 ADULT HPN

9.6.2 PEDIATRIC HPN

9.7 ASIA-PACIFIC HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

9.7.1 LONG-TERM HPN

9.7.2 SHORT-TERM HPN

9.8 ASIA-PACIFIC ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.8.1 ORAL FEEDING

9.8.2 TUBE FEEDING

9.8.3 FORMULA TYPE

9.9 ASIA-PACIFIC TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.9.1 NASOGASTRIC (NG)

9.9.2 PEG FEEDING

9.9.3 JEJUNOSTOMY FEEDING

9.1 ASIA-PACIFIC FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.10.1 POLYMERIC

9.10.2 ELEMENTAL

9.10.3 SEMI-ELEMENTAL

9.11 ASIA-PACIFIC PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.11.1 MACRONUTRIENTS

9.11.2 ELECTROLYTES & FLUIDS

9.11.3 MICRONUTRIENTS

9.12 ASIA-PACIFIC MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.12.1 AMINO ACIDS

9.12.2 LIPID EMULSIONS

9.12.3 DEXTROSE

9.13 ASIA-PACIFIC MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.13.1 VITAMINS

9.13.2 TRACE ELEMENTS

9.14 ASIA-PACIFIC NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

9.14.1 NORTH AMERICA

9.14.2 EUROPE

9.14.3 ASIA-PACIFIC

9.14.4 MIDDLE EAST AND AFRICA

9.14.5 SOUTH AMERICA

9.15 ASIA-PACIFIC PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.15.1 HORMONAL & INTESTINAL ADAPTATION THERAPY

9.15.2 ANTI-DIARRHEAL THERAPY

9.15.3 ANTI-SECRETORY THERAPY

9.15.4 MICRONUTRIENT SUPPLEMENTATION

9.15.5 ANTI-INFECTIVE THERAPY

9.15.6 BILE ACID & ABSORPTION MODIFIERS

9.16 ASIA-PACIFIC HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.16.1 GLP-2 ANALOGUES

9.16.2 GROWTH HORMONE THERAPY

9.16.3 IGF-1 & ANALOGUES

9.17 ASIA-PACIFIC GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.17.1 TEDUGLUTIDE

9.17.2 APRAGLUTIDE (LATE-STAGE)

9.17.3 LONG-ACTING GLP-2 ANALOGUES

9.18 ASIA-PACIFIC GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

9.18.1 HUMATROPE

9.18.2 NORDITROPIN

9.18.3 GENOTROPIN

9.19 ASIA-PACIFIC IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.19.1 INCRELEX

9.19.2 OTHERS

9.2 ASIA-PACIFIC ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.20.1 OPIOID-BASED

9.20.2 NON-OPIOID AGENTS

9.21 ASIA-PACIFIC OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.21.1 LOPERAMIDE

9.21.2 CODEINE

9.22 ASIA-PACIFIC ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.22.1 PROTON PUMP INHIBITORS

9.22.2 SOMATOSTATIN ANALOGUES

9.22.3 H2 RECEPTOR ANTAGONISTS

9.23 ASIA-PACIFIC PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.23.1 OMEPRAZOLE

9.23.2 PANTOPRAZOLE

9.23.3 ESOMEPRAZOLE

9.23.4 OTHERS

9.24 ASIA-PACIFIC SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

9.24.1 OCTREOTIDE

9.24.2 OTHERS

9.25 ASIA-PACIFIC H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.25.1 FAMOTIDINE

9.25.2 OTHERS

9.26 ASIA-PACIFIC MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.26.1 FAT-SOLUBLE VITAMINS (A, D, E, K)

9.26.2 ELECTROLYTES

9.26.3 VITAMIN B12

9.26.4 MINERAL SUPPLEMENTATION

9.27 ASIA-PACIFIC ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.27.1 BROAD-SPECTRUM ANTIBIOTICS

9.27.2 SIBO-TARGETED THERAPY

9.28 ASIA-PACIFIC BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.28.1 BILE ACID SEQUESTRANTS

9.28.2 FAT ABSORPTION ENHANCERS

9.29 ASIA-PACIFIC BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.29.1 CHOLESTYRAMINE

9.29.2 COLESEVELAM

9.29.3 OTHERS

9.3 ASIA-PACIFIC PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

9.30.1 NORTH AMERICA

9.30.2 EUROPE

9.30.3 ASIA-PACIFIC

9.30.4 MIDDLE EAST AND AFRICA

9.30.5 SOUTH AMERICA

9.31 ASIA-PACIFIC SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.31.1 INTESTINAL LENGTHENING PROCEDURES

9.31.2 OSTOMY & RECONSTRUCTION

9.31.3 INTESTINAL TRANSPLANTATION

9.32 ASIA-PACIFIC INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.32.1 STEP PROCEDURE

9.32.2 BIANCHI PROCEDURE

9.33 ASIA-PACIFIC OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.33.1 ILEOSTOMY

9.33.2 JEJUNOSTOMY

9.33.3 REVERSAL SURGERY

9.34 ASIA-PACIFIC INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.34.1 ISOLATED SMALL BOWEL

9.34.2 LIVER + INTESTINE

9.34.3 MULTIVISCERAL TRANSPLANT

9.35 ASIA-PACIFIC SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

9.35.1 NORTH AMERICA

9.35.2 EUROPE

9.35.3 ASIA-PACIFIC

9.35.4 MIDDLE EAST AND AFRICA

9.35.5 SOUTH AMERICA

9.36 ASIA-PACIFIC EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.36.1 REGENERATIVE MEDICINE

9.36.2 MICROBIOME-BASED THERAPY

9.36.3 GENE THERAPY

9.37 ASIA-PACIFIC REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.37.1 STEM CELL THERAPY

9.37.2 TISSUE-ENGINEERED INTESTINE

9.38 ASIA-PACIFIC MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.38.1 PROBIOTICS

9.38.2 FMT

9.39 ASIA-PACIFIC GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.39.1 ABSORPTIVE FUNCTION TARGETING

9.39.2 MUCOSAL GROWTH MODULATION

9.4 ASIA-PACIFIC EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

9.40.1 NORTH AMERICA

9.40.2 EUROPE

9.40.3 ASIA-PACIFIC

9.40.4 MIDDLE EAST AND AFRICA

9.40.5 SOUTH AMERICA

10 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION

10.1 OVERVIEW

10.2 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

10.2.1 CORE SBS-IF MARKET

10.2.2 SBS-IF ATTRIBUTABLE MARKET

10.2.3 ADJACENT / NON-SPECIFIC MARKET

10.3 ASIA-PACIFIC CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

10.3.1 PARENTERAL NUTRITION

10.3.2 GLP-2 ANALOGUES

10.4 ASIA-PACIFIC CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

10.4.1 NORTH AMERICA

10.4.2 EUROPE

10.4.3 ASIA-PACIFIC

10.4.4 MIDDLE EAST AND AFRICA

10.4.5 SOUTH AMERICA

10.5 ASIA-PACIFIC SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

10.5.1 ANTI-DIARRHEALS

10.5.2 PPIS

10.5.3 ANTIBIOTICS

10.6 ASIA-PACIFIC SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

10.6.1 NORTH AMERICA

10.6.2 EUROPE

10.6.3 ASIA-PACIFIC

10.6.4 MIDDLE EAST AND AFRICA

10.6.5 SOUTH AMERICA

10.7 ASIA-PACIFIC ADJACENT / NON-SPECIFIC MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

10.7.1 NORTH AMERICA

10.7.2 EUROPE

10.7.3 ASIA-PACIFIC

10.7.4 MIDDLE EAST AND AFRICA

10.7.5 SOUTH AMERICA

11 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE

11.1 OVERVIEW

11.2 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

11.2.1 ACUTE PHASE (TYPE 1 SBS-IF)

11.2.2 ADAPTATION PHASE

11.2.3 RECOVERY PHASE

11.3 ASIA-PACIFIC ACUTE PHASE (TYPE 1 SBS-IF) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

11.3.1 NORTH AMERICA

11.3.2 EUROPE

11.3.3 ASIA-PACIFIC

11.3.4 MIDDLE EAST AND AFRICA

11.3.5 SOUTH AMERICA

11.4 ASIA-PACIFIC ADAPTATION PHASE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

11.4.1 NORTH AMERICA

11.4.2 EUROPE

11.4.3 ASIA-PACIFIC

11.4.4 MIDDLE EAST AND AFRICA

11.4.5 SOUTH AMERICA

11.5 ASIA-PACIFIC RECOVERY PHASE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

11.5.1 NORTH AMERICA

11.5.2 EUROPE

11.5.3 ASIA-PACIFIC

11.5.4 MIDDLE EAST AND AFRICA

11.5.5 SOUTH AMERICA

12 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE

12.1 OVERVIEW

12.2 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

12.2.1 ADULT

12.2.2 PEDIATRIC

12.3 ASIA-PACIFIC ADULT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

12.3.1 NORTH AMERICA

12.3.2 EUROPE

12.3.3 ASIA-PACIFIC

12.3.4 MIDDLE EAST AND AFRICA

12.3.5 SOUTH AMERICA

12.4 ASIA-PACIFIC PEDIATRIC IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

12.4.1 NORTH AMERICA

12.4.2 EUROPE

12.4.3 ASIA-PACIFIC

12.4.4 MIDDLE EAST AND AFRICA

12.4.5 SOUTH AMERICA

13 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

13.1 OVERVIEW

13.2 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

13.2.1 INTRAVENOUS

13.2.2 SUBCUTANEOUS

13.2.3 ORAL

13.2.4 ENTERAL

13.3 ASIA-PACIFIC INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

13.3.1 PN

13.3.2 INJECTABLES

13.4 ASIA-PACIFIC INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

13.4.1 NORTH AMERICA

13.4.2 EUROPE

13.4.3 ASIA-PACIFIC

13.4.4 MIDDLE EAST AND AFRICA

13.4.5 SOUTH AMERICA

13.5 ASIA-PACIFIC SUBCUTANEOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

13.5.1 NORTH AMERICA

13.5.2 EUROPE

13.5.3 ASIA-PACIFIC

13.5.4 MIDDLE EAST AND AFRICA

13.5.5 SOUTH AMERICA

13.6 ASIA-PACIFIC ORAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

13.6.1 NORTH AMERICA

13.6.2 EUROPE

13.6.3 ASIA-PACIFIC

13.6.4 MIDDLE EAST AND AFRICA

13.6.5 SOUTH AMERICA

13.7 ASIA-PACIFIC ENTERAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

13.7.1 NORTH AMERICA

13.7.2 EUROPE

13.7.3 ASIA-PACIFIC

13.7.4 MIDDLE EAST AND AFRICA

13.7.5 SOUTH AMERICA

14 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER

14.1 OVERVIEW

14.2 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

14.2.1 HOSPITALS (ACUTE CARE)

14.2.2 HOME CARE (HPN PROGRAMS)

14.2.3 ICU SETTINGS

14.2.4 PECIALTY GI CENTERS

14.2.5 PEDIATRIC SPECIALTY HOSPITALS

14.3 ASIA-PACIFIC HOSPITALS (ACUTE CARE) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

14.3.1 NORTH AMERICA

14.3.2 EUROPE

14.3.3 ASIA-PACIFIC

14.3.4 MIDDLE EAST AND AFRICA

14.3.5 SOUTH AMERICA

14.4 ASIA-PACIFIC HOME CARE (HPN PROGRAMS) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

14.4.1 NORTH AMERICA

14.4.2 EUROPE

14.4.3 ASIA-PACIFIC

14.4.4 MIDDLE EAST AND AFRICA

14.4.5 SOUTH AMERICA

14.5 ASIA-PACIFIC ICU SETTINGS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

14.5.1 NORTH AMERICA

14.5.2 EUROPE

14.5.3 ASIA-PACIFIC

14.5.4 MIDDLE EAST AND AFRICA

14.5.5 SOUTH AMERICA

14.6 ASIA-PACIFIC SPECIALTY GI CENTERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

14.6.1 NORTH AMERICA

14.6.2 EUROPE

14.6.3 ASIA-PACIFIC

14.6.4 MIDDLE EAST AND AFRICA

14.6.5 SOUTH AMERICA

14.7 ASIA-PACIFIC PEDIATRIC SPECIALTY HOSPITALS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

14.7.1 NORTH AMERICA

14.7.2 EUROPE

14.7.3 ASIA-PACIFIC

14.7.4 MIDDLE EAST AND AFRICA

14.7.5 SOUTH AMERICA

15 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

15.2.1 HOSPITAL PHARMACY

15.2.2 SPECIALTY PHARMACY

15.2.3 RETAIL PHARMACY

15.2.4 ONLINE PHARMACY

15.3 ASIA-PACIFIC HOSPITAL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

15.3.1 NORTH AMERICA

15.3.2 EUROPE

15.3.3 ASIA-PACIFIC

15.3.4 MIDDLE EAST AND AFRICA

15.3.5 SOUTH AMERICA

15.4 ASIA-PACIFIC SPECIALTY PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

15.4.1 NORTH AMERICA

15.4.2 EUROPE

15.4.3 ASIA-PACIFIC

15.4.4 MIDDLE EAST AND AFRICA

15.4.5 SOUTH AMERICA

15.5 ASIA-PACIFIC RETAIL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

15.5.1 NORTH AMERICA

15.5.2 EUROPE

15.5.3 ASIA-PACIFIC

15.5.4 MIDDLE EAST AND AFRICA

15.5.5 SOUTH AMERICA

16 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION

16.1 ASIA PACIFIC

16.1.1 JAPAN

16.1.2 CHINA

16.1.3 SOUTH KOREA

16.1.4 INDIA

16.1.5 SINGAPORE

16.1.6 THAILAND

16.1.7 INDONESIA

16.1.8 MALAYSIA

16.1.9 PHILIPPINES

16.1.10 BELGIUM

16.1.11 NEW ZEALAND

16.1.12 HONG KONG

16.1.13 TAIWAN

16.1.14 REST OF ASIA-PACIFIC

17 ASIA-PACIFIC ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: COMPANY LANDSCAPE

17.1 MANUFACTURER COMPANY SHARE ANALYSIS: GLOBAL

18 SWOT ANALYSIS

19 COMPANY PROFILES

19.1 FRESENIUS KABI

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENT

19.2 BAXTER INTERNATIONAL INC.

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENT

19.3 NESTLÉ HEALTH SCIENCE

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENT

19.4 ABBOTT LABORATORIES

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENT

19.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 COMPANY SHARE ANALYSIS

19.5.4 PRODUCT PORTFOLIO

19.5.5 RECENT DEVELOPMENT

19.6 MOOG COMPANY

19.6.1 COMPANY SNAPSHOT

19.6.2 REVENUE ANALYSIS

19.6.3 PRODUCT PORTFOLIO

19.6.4 RECENT DEVELOPMENT/NEWS

19.7 ACULIFE HEALTHCARE

19.7.1 COMPANY SNAPSHOT

19.7.2 PRODUCT PORTFOLIO

19.7.3 RECENT DEVELOPMENT

19.8 AMSINO INTERNATIONAL, INC

19.8.1 COMPANY SNAPSHOT

19.8.2 PRODUCT PORTFOLIO

19.8.3 RECENT DEVELOPMENT

19.9 AURORA HEALTH CARE

19.9.1 COMPANY SNAPSHOT

19.9.2 PRODUCT PORTFOLIO

19.9.3 RECENT DEVELOPMENT

19.1 AMERIPHARMA SPECIALTY CARE.

19.10.1 COMPANY SNAPSHOT

19.10.2 PRODUCT PORTFOLIO

19.10.3 RECENT DEVELOPMENT

19.11 BAUSCH HEALTH COMPANIES INC

19.11.1 COMPANY SNAPSHOT

19.11.2 REVENUE ANALYSIS

19.11.3 PRODUCT PORTFOLIO

19.11.4 RECENT DEVELOPMENT

19.12 BEVELRYHILLS DIGESTIVE CARE

19.12.1 COMPANY SNAPSHOT

19.12.2 PRODUCT PORTFOLIO

19.12.3 RECENT DEVELOPMENT

19.13 B. BRAUN SE

19.13.1 COMPANY SNAPSHOT

19.13.2 PRODUCT PORTFOLIO

19.13.3 RECENT DEVELOPMENT

19.14 CAMVITTA

19.14.1 COMPANY SNAPSHOT

19.14.2 PRODUCT PORTFOLIO

19.14.3 RECENT DEVELOPMENT

19.15 CHOICE PARENTERAL NUTRITION LLC

19.15.1 COMPANY SNAPSHOT

19.15.2 PRODUCT PORTFOLIO

19.15.3 RECENT DEVELOPMENT

19.16 CONTINUUMRX

19.16.1 COMPANY SNAPSHOT

19.16.2 PRODUCT PORTFOLIO

19.16.3 RECENT DEVELOPMENT

19.17 FERRING PHARMACEUTICALS

19.17.1 COMPANY SNAPSHOT

19.17.2 PRODUCT PORTFOLIO

19.17.3 RECENT DEVELOPMENT

19.18 GRIFOLS S.A.

19.18.1 COMPANY SNAPSHOT

19.18.2 REVENUE ANALYSIS

19.18.3 PRODUCT PORTFOLIO

19.18.4 RECENT DEVELOPMENT

19.19 HIKMA PHARMACEUTICALS

19.19.1 COMPANY SNAPSHOT

19.19.2 REVENUE ANALYSIS

19.19.3 PRODUCT PORTFOLIO

19.19.4 RECENT DEVELOPMENT

19.2 HOSPIRA (PART OF PFIZER INC.)

19.20.1 COMPANY SNAPSHOT

19.20.2 REVENUE ANALYSIS

19.20.3 PRODUCT PORTFOLIO

19.20.4 RECENT DEVELOPMENT

19.21 HANMI PHARM.CO.,LTD.

19.21.1 COMPANY SNAPSHOT

19.21.2 REVENUE ANALYSIS

19.21.3 PRODUCT PORTFOLIO

19.21.4 RECENT DEVELOPMENT

19.22 ICU MEDICAL, INC.

19.22.1 COMPANY SNAPSHOT

19.22.2 REVENUE ANALYSIS

19.22.3 PRODUCT PORTFOLIO

19.22.4 RECENT DEVELOPMENT

19.23 INFUSION SOLUTIONS

19.23.1 COMPANY SNAPSHOT

19.23.2 PRODUCT PORTFOLIO

19.23.3 RECENT DEVELOPMENT

19.24 INTEGRATED CARE SYSTEMS

19.24.1 COMPANY SNAPSHOT

19.24.2 PRODUCT PORTFOLIO

19.24.3 RECENT DEVELOPMENT

19.25 JEDUX PARENTERAL PRIVATE LIMITED

19.25.1 COMPANY SNAPSHOT

19.25.2 PRODUCT PORTFOLIO

19.25.3 RECENT DEVELOPMENT

19.26 LABORATOIRE DIELEN

19.26.1 COMPANY SNAPSHOT

19.26.2 PRODUCT PORTFOLIO

19.26.3 RECENT DEVELOPMENT

19.27 NAPO THERAPEUTICS.

19.27.1 COMPANY SNAPSHOT

19.27.2 PRODUCT PORTFOLIO

19.27.3 RECENT DEVELOPMENT/NEWS

19.28 NUTREGO

19.28.1 COMPANY SNAPSHOT

19.28.2 PRODUCT PORTFOLIO

19.28.3 RECENT DEVELOPMENT

19.29 NUTRICIA (DANONE GROUP)

19.29.1 COMPANY SNAPSHOT

19.29.2 REVENUE ANALYSIS

19.29.3 PRODUCT PORTFOLIO

19.29.4 RECENT DEVELOPMENT

19.3 NUTRICIA NORTH AMERICA

19.30.1 COMPANY SNAPSHOTS

19.30.2 PRODUCT PORTFOLIO

19.30.3 RECENT DEVELOPMENT

19.31 NUTRISHARE

19.31.1 COMPANY SNAPSHOT

19.31.2 PRODUCT PORTFOLIO

19.31.3 RECENT DEVELOPMENT

19.32 OXTHERA

19.32.1 COMPANY SNAPSHOT

19.32.2 PRODUCT PORTFOLIO

19.32.3 RECENT DEVELOPMENT

19.33 PHARMKO, INC.

19.33.1 COMPANY SNAPSHOT

19.33.2 PRODUCT PORTFOLIO

19.33.3 RECENT DEVELOPMENT

19.34 PUERTO LIFE SCIENCES PVT. LTD.

19.34.1 COMPANY SNAPSHOT

19.34.2 PRODUCT PORTFOLIO

19.34.3 RECENT DEVELOPMENT

19.35 SHANDONG QIDU PHARMACEUTICAL CO., LTD.

19.35.1 COMPANY SNAPSHOT

19.35.2 PRODUCT PORTFOLIO

19.35.3 RECENT DEVELOPMENT

19.36 STANFORD HEALTH CARE

19.36.1 COMPANY SNAPSHOT

19.36.2 PRODUCT PORTFOLIO

19.36.3 RECENT DEVELOPMENT

19.37 UF HEALTH

19.37.1 COMPANY SNAPSHOT

19.37.2 PRODUCT PORTFOLIO

19.37.3 RECENT DEVELOPMENT

19.38 IRONWOOD PHARMACEUTICALS

19.38.1 COMPANY SNAPSHOT

19.38.2 REVENUE ANALYSIS

19.38.3 PRODUCT PORTFOLIO

19.38.4 RECENT DEVELOPMENT

19.39 VISION PARENTERAL

19.39.1 COMPANY SNAPSHOT

19.39.2 PRODUCT PORTFOLIO

19.39.3 RECENT DEVELOPMENT

19.4 ZEALAND PHARMA

19.40.1 COMPANY SNAPSHOT

19.40.2 REVENUE ANALYSIS

19.40.3 PRODUCT PORTFOLIO

19.40.4 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

List of Table

TABLE 1 TREATMENT RATE OF SBI-IF PATIENTS

TABLE 2 ESTIMATED THERAPY-SPECIFIC PATIENT POOLS

TABLE 3 ESTIMATED FUNNEL PATEGINTS

TABLE 4 KEY INDUSTRY INSIGHTS AND MARKET TRENDS IN THE ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET

TABLE 5 IMPACT OF WAR-DRIVEN DISRUPTIONS ON THE ASIA-PACIFIC TYPE 1 SBS-IF TREATMENT MARKET ECOSYSTEM AND INDUSTRY RESPONSE FRAMEWORK

TABLE 6 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE ASIA-PACIFIC TYPE 1 SBS-IF MARKET

TABLE 7 DISTRIBUTION OF OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE – ASIA-PACIFIC TYPE 1 SBS-IF MARKET

TABLE 8 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE – ASIA-PACIFIC TYPE 1 SBS-IF MARKET

TABLE 9 PIPELINE LANDSCAPE AND CLINICAL DEVELOPMENT OVERVIEW

TABLE 10 TOP ENTITIES BASED ON R&D GLANCE – ASIA-PACIFIC TYPE 1 SBS-IF TREATMENT MARKET

TABLE 11 PRECLINICAL / RESEARCH STAGE VACCINE CANDIDATES

TABLE 12 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 13 ASIA-PACIFIC NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 14 ASIA-PACIFIC PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 15 ASIA-PACIFIC TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 16 ASIA-PACIFIC HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 17 ASIA-PACIFIC HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 18 ASIA-PACIFIC ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 19 ASIA-PACIFIC TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 20 ASIA-PACIFIC FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 21 ASIA-PACIFIC PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 22 ASIA-PACIFIC MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 23 ASIA-PACIFIC MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 24 ASIA-PACIFIC NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 25 ASIA-PACIFIC PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 26 ASIA-PACIFIC HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 27 ASIA-PACIFIC GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 28 ASIA-PACIFIC GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 29 ASIA-PACIFIC IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 30 ASIA-PACIFIC ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 31 ASIA-PACIFIC OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 32 ASIA-PACIFIC ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 33 ASIA-PACIFIC PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 34 ASIA-PACIFIC SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 35 ASIA-PACIFIC H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 36 ASIA-PACIFIC MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 37 ASIA-PACIFIC ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 38 ASIA-PACIFIC BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 39 ASIA-PACIFIC BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 40 ASIA-PACIFIC PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 41 ASIA-PACIFIC SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 42 ASIA-PACIFIC INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 43 ASIA-PACIFIC OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 44 ASIA-PACIFIC INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 45 ASIA-PACIFIC SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 46 ASIA-PACIFIC EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 47 ASIA-PACIFIC REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 48 ASIA-PACIFIC MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 49 ASIA-PACIFIC GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 50 ASIA-PACIFIC EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 51 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 52 ASIA-PACIFIC CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 53 ASIA-PACIFIC CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 54 ASIA-PACIFIC SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 55 ASIA-PACIFIC SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 56 ASIA-PACIFIC ADJACENT / NON-SPECIFIC MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 57 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 58 ASIA-PACIFIC ACUTE PHASE (TYPE 1 SBS-IF) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 59 ASIA-PACIFIC ADAPTATION PHASE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 60 ASIA-PACIFIC RECOVERY PHASE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 61 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 62 ASIA-PACIFIC ADULT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 63 ASIA-PACIFIC PEDIATRIC IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 64 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 65 ASIA-PACIFIC INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 66 ASIA-PACIFIC INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 67 ASIA-PACIFIC SUBCUTANEOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 68 ASIA-PACIFIC ORAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 69 ASIA-PACIFIC ENTERAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 70 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 71 ASIA-PACIFIC HOSPITALS (ACUTE CARE) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 72 ASIA-PACIFIC HOME CARE (HPN PROGRAMS) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 73 ASIA-PACIFIC ICU SETTINGS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 74 ASIA-PACIFIC SPECIALTY GI CENTERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 75 ASIA-PACIFIC PEDIATRIC SPECIALTY HOSPITALS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 76 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 77 ASIA-PACIFIC HOSPITAL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 78 ASIA-PACIFIC SPECIALTY PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 79 ASIA-PACIFIC RETAIL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 80 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, 2018-2033 (USD THOUSAND)

TABLE 81 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY COUNTRY, 2018-2033 (USD THOUSAND)

TABLE 82 USD THOUSAND

TABLE 83 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 84 ASIA-PACIFIC NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 85 ASIA-PACIFIC PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 86 ASIA-PACIFIC TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 87 ASIA-PACIFIC HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 88 ASIA-PACIFIC HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 89 ASIA-PACIFIC ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 90 ASIA-PACIFIC TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 91 ASIA-PACIFIC FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 92 ASIA-PACIFIC PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 93 ASIA-PACIFIC MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 94 ASIA-PACIFIC MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 95 ASIA-PACIFIC PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 96 ASIA-PACIFIC HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 97 ASIA-PACIFIC GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 98 ASIA-PACIFIC GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 99 ASIA-PACIFIC IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 100 ASIA-PACIFIC ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 101 ASIA-PACIFIC OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 102 ASIA-PACIFIC ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 103 ASIA-PACIFIC PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 104 ASIA-PACIFIC SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 105 ASIA-PACIFIC H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 106 ASIA-PACIFIC MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 107 ASIA-PACIFIC ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 108 ASIA-PACIFIC BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 109 ASIA-PACIFIC BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 110 ASIA-PACIFIC SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 111 ASIA-PACIFIC INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 112 ASIA-PACIFIC OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 113 ASIA-PACIFIC INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 114 ASIA-PACIFIC EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 115 ASIA-PACIFIC REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 116 ASIA-PACIFIC MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 117 ASIA-PACIFIC GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 118 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 119 ASIA-PACIFIC CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 120 ASIA-PACIFIC SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 121 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 122 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 123 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 124 ASIA-PACIFIC INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 125 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 126 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 127 USD THOUSAND

TABLE 128 JAPAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 129 JAPAN NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 130 JAPAN PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 131 JAPAN TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 132 JAPAN HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 133 JAPAN HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 134 JAPAN ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 135 JAPAN TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 136 JAPAN FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 137 JAPAN PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 138 JAPAN MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 139 JAPAN MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 140 JAPAN PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 141 JAPAN HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 142 JAPAN GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 143 JAPAN GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 144 JAPAN IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 145 JAPAN ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 146 JAPAN OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 147 JAPAN ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 148 JAPAN PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 149 JAPAN SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 150 JAPAN H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 151 JAPAN MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 152 JAPAN ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 153 JAPAN BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 154 JAPAN BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 155 JAPAN SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 156 JAPAN INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 157 JAPAN OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 158 JAPAN INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 159 JAPAN EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 160 JAPAN REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 161 JAPAN MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 162 JAPAN GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 163 JAPAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 164 JAPAN CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 165 JAPAN SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 166 JAPAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 167 JAPAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 168 JAPAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 169 JAPAN INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 170 JAPAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 171 JAPAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 172 USD THOUSAND

TABLE 173 CHINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 174 CHINA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 175 CHINA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 176 CHINA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 177 CHINA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 178 CHINA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 179 CHINA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 180 CHINA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 181 CHINA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 182 CHINA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 183 CHINA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 184 CHINA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 185 CHINA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 186 CHINA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 187 CHINA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 188 CHINA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 189 CHINA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 190 CHINA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 191 CHINA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 192 CHINA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 193 CHINA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 194 CHINA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 195 CHINA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 196 CHINA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 197 CHINA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 198 CHINA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 199 CHINA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 200 CHINA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 201 CHINA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 202 CHINA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 203 CHINA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 204 CHINA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 205 CHINA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 206 CHINA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 207 CHINA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 208 CHINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 209 CHINA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 210 CHINA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 211 CHINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 212 CHINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 213 CHINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 214 CHINA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 215 CHINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 216 CHINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 217 USD THOUSAND

TABLE 218 SOUTH KOREA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 219 SOUTH KOREA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 220 SOUTH KOREA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 221 SOUTH KOREA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 222 SOUTH KOREA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 223 SOUTH KOREA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 224 SOUTH KOREA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 225 SOUTH KOREA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 226 SOUTH KOREA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 227 SOUTH KOREA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 228 SOUTH KOREA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 229 SOUTH KOREA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 230 SOUTH KOREA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 231 SOUTH KOREA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 232 SOUTH KOREA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 233 SOUTH KOREA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 234 SOUTH KOREA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 235 SOUTH KOREA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 236 SOUTH KOREA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 237 SOUTH KOREA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 238 SOUTH KOREA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 239 SOUTH KOREA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 240 SOUTH KOREA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 241 SOUTH KOREA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 242 SOUTH KOREA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 243 SOUTH KOREA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 244 SOUTH KOREA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 245 SOUTH KOREA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 246 SOUTH KOREA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 247 SOUTH KOREA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 248 SOUTH KOREA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 249 SOUTH KOREA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 250 SOUTH KOREA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 251 SOUTH KOREA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 252 SOUTH KOREA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 253 SOUTH KOREA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 254 SOUTH KOREA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 255 SOUTH KOREA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 256 SOUTH KOREA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 257 SOUTH KOREA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 258 SOUTH KOREA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 259 SOUTH KOREA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 260 SOUTH KOREA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 261 SOUTH KOREA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 262 USD THOUSAND

TABLE 263 INDIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 264 INDIA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 265 INDIA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 266 INDIA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 267 INDIA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 268 INDIA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 269 INDIA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 270 INDIA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 271 INDIA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 272 INDIA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 273 INDIA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 274 INDIA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 275 INDIA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 276 INDIA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 277 INDIA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 278 INDIA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 279 INDIA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 280 INDIA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 281 INDIA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 282 INDIA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 283 INDIA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 284 INDIA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 285 INDIA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 286 INDIA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 287 INDIA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 288 INDIA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 289 INDIA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 290 INDIA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 291 INDIA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 292 INDIA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 293 INDIA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 294 INDIA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 295 INDIA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 296 INDIA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 297 INDIA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 298 INDIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 299 INDIA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 300 INDIA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 301 INDIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 302 INDIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 303 INDIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 304 INDIA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 305 INDIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 306 INDIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 307 USD THOUSAND

TABLE 308 SINGAPORE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 309 SINGAPORE NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 310 SINGAPORE PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 311 SINGAPORE TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 312 SINGAPORE HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 313 SINGAPORE HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 314 SINGAPORE ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 315 SINGAPORE TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 316 SINGAPORE FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 317 SINGAPORE PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 318 SINGAPORE MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 319 SINGAPORE MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 320 SINGAPORE PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 321 SINGAPORE HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 322 SINGAPORE GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 323 SINGAPORE GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 324 SINGAPORE IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 325 SINGAPORE ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 326 SINGAPORE OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 327 SINGAPORE ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 328 SINGAPORE PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 329 SINGAPORE SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 330 SINGAPORE H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 331 SINGAPORE MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 332 SINGAPORE ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 333 SINGAPORE BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 334 SINGAPORE BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 335 SINGAPORE SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 336 SINGAPORE INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 337 SINGAPORE OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 338 SINGAPORE INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 339 SINGAPORE EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 340 SINGAPORE REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 341 SINGAPORE MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 342 SINGAPORE GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 343 SINGAPORE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 344 SINGAPORE CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 345 SINGAPORE SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 346 SINGAPORE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 347 SINGAPORE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 348 SINGAPORE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 349 SINGAPORE INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 350 SINGAPORE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 351 SINGAPORE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 352 USD THOUSAND

TABLE 353 THAILAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 354 THAILAND NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 355 THAILAND PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 356 THAILAND TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 357 THAILAND HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 358 THAILAND HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 359 THAILAND ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 360 THAILAND TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 361 THAILAND FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 362 THAILAND PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 363 THAILAND MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 364 THAILAND MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 365 THAILAND PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 366 THAILAND HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 367 THAILAND GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 368 THAILAND GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 369 THAILAND IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 370 THAILAND ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 371 THAILAND OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 372 THAILAND ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 373 THAILAND PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 374 THAILAND SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 375 THAILAND H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 376 THAILAND MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 377 THAILAND ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 378 THAILAND BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 379 THAILAND BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 380 THAILAND SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 381 THAILAND INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 382 THAILAND OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 383 THAILAND INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 384 THAILAND EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 385 THAILAND REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 386 THAILAND MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 387 THAILAND GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 388 THAILAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 389 THAILAND CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 390 THAILAND SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 391 THAILAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 392 THAILAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 393 THAILAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 394 THAILAND INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 395 THAILAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 396 THAILAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 397 USD THOUSAND

TABLE 398 INDONESIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 399 INDONESIA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 400 INDONESIA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 401 INDONESIA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 402 INDONESIA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 403 INDONESIA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 404 INDONESIA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 405 INDONESIA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 406 INDONESIA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 407 INDONESIA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 408 INDONESIA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 409 INDONESIA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 410 INDONESIA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 411 INDONESIA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 412 INDONESIA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 413 INDONESIA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 414 INDONESIA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 415 INDONESIA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 416 INDONESIA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 417 INDONESIA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 418 INDONESIA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 419 INDONESIA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 420 INDONESIA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 421 INDONESIA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 422 INDONESIA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 423 INDONESIA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 424 INDONESIA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 425 INDONESIA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 426 INDONESIA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 427 INDONESIA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 428 INDONESIA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 429 INDONESIA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 430 INDONESIA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 431 INDONESIA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 432 INDONESIA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 433 INDONESIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 434 INDONESIA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 435 INDONESIA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 436 INDONESIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 437 INDONESIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 438 INDONESIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 439 INDONESIA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 440 INDONESIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 441 INDONESIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 442 USD THOUSAND

TABLE 443 MALAYSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 444 MALAYSIA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 445 MALAYSIA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 446 MALAYSIA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 447 MALAYSIA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 448 MALAYSIA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 449 MALAYSIA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 450 MALAYSIA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 451 MALAYSIA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 452 MALAYSIA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 453 MALAYSIA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 454 MALAYSIA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 455 MALAYSIA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 456 MALAYSIA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 457 MALAYSIA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 458 MALAYSIA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 459 MALAYSIA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 460 MALAYSIA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 461 MALAYSIA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 462 MALAYSIA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 463 MALAYSIA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 464 MALAYSIA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 465 MALAYSIA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 466 MALAYSIA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 467 MALAYSIA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 468 MALAYSIA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 469 MALAYSIA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 470 MALAYSIA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 471 MALAYSIA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 472 MALAYSIA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 473 MALAYSIA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 474 MALAYSIA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 475 MALAYSIA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 476 MALAYSIA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 477 MALAYSIA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 478 MALAYSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 479 MALAYSIA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 480 MALAYSIA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 481 MALAYSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 482 MALAYSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 483 MALAYSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 484 MALAYSIA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 485 MALAYSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 486 MALAYSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 487 USD THOUSAND

TABLE 488 PHILIPPINES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 489 PHILIPPINES NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 490 PHILIPPINES PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 491 PHILIPPINES TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 492 PHILIPPINES HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 493 PHILIPPINES HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 494 PHILIPPINES ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 495 PHILIPPINES TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 496 PHILIPPINES FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 497 PHILIPPINES PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 498 PHILIPPINES MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 499 PHILIPPINES MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 500 PHILIPPINES PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 501 PHILIPPINES HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 502 PHILIPPINES GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 503 PHILIPPINES GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 504 PHILIPPINES IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 505 PHILIPPINES ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 506 PHILIPPINES OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 507 PHILIPPINES ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 508 PHILIPPINES PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 509 PHILIPPINES SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 510 PHILIPPINES H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 511 PHILIPPINES MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 512 PHILIPPINES ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 513 PHILIPPINES BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 514 PHILIPPINES BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 515 PHILIPPINES SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 516 PHILIPPINES INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 517 PHILIPPINES OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 518 PHILIPPINES INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 519 PHILIPPINES EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 520 PHILIPPINES REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 521 PHILIPPINES MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 522 PHILIPPINES GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 523 PHILIPPINES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 524 PHILIPPINES CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 525 PHILIPPINES SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 526 PHILIPPINES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 527 PHILIPPINES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 528 PHILIPPINES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 529 PHILIPPINES INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 530 PHILIPPINES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 531 PHILIPPINES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 532 USD THOUSAND

TABLE 533 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 534 BELGIUM NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 535 BELGIUM PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 536 BELGIUM TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 537 BELGIUM HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 538 BELGIUM HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 539 BELGIUM ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 540 BELGIUM TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 541 BELGIUM FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 542 BELGIUM PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 543 BELGIUM MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 544 BELGIUM MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 545 BELGIUM PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 546 BELGIUM HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 547 BELGIUM GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 548 BELGIUM GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 549 BELGIUM IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 550 BELGIUM ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 551 BELGIUM OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 552 BELGIUM ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 553 BELGIUM PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 554 BELGIUM SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 555 BELGIUM H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 556 BELGIUM MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 557 BELGIUM ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 558 BELGIUM BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 559 BELGIUM BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 560 BELGIUM SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 561 BELGIUM INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 562 BELGIUM OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 563 BELGIUM INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 564 BELGIUM EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 565 BELGIUM REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 566 BELGIUM MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 567 BELGIUM GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 568 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 569 BELGIUM CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 570 BELGIUM SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 571 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 572 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 573 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 574 BELGIUM INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 575 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 576 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 577 USD THOUSAND

TABLE 578 NEW ZEALAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 579 NEW ZEALAND NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 580 NEW ZEALAND PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 581 NEW ZEALAND TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 582 NEW ZEALAND HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 583 NEW ZEALAND HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 584 NEW ZEALAND ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 585 NEW ZEALAND TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 586 NEW ZEALAND FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 587 NEW ZEALAND PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 588 NEW ZEALAND MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 589 NEW ZEALAND MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 590 NEW ZEALAND PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 591 NEW ZEALAND HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 592 NEW ZEALAND GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 593 NEW ZEALAND GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 594 NEW ZEALAND IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 595 NEW ZEALAND ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 596 NEW ZEALAND OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 597 NEW ZEALAND ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 598 NEW ZEALAND PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 599 NEW ZEALAND SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 600 NEW ZEALAND H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 601 NEW ZEALAND MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 602 NEW ZEALAND ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 603 NEW ZEALAND BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 604 NEW ZEALAND BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 605 NEW ZEALAND SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 606 NEW ZEALAND INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 607 NEW ZEALAND OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 608 NEW ZEALAND INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 609 NEW ZEALAND EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 610 NEW ZEALAND REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 611 NEW ZEALAND MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 612 NEW ZEALAND GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 613 NEW ZEALAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 614 NEW ZEALAND CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 615 NEW ZEALAND SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 616 NEW ZEALAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 617 NEW ZEALAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 618 NEW ZEALAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 619 NEW ZEALAND INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 620 NEW ZEALAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 621 NEW ZEALAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 622 USD THOUSAND

TABLE 623 HONG KONG TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 624 HONG KONG NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 625 HONG KONG PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 626 HONG KONG TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 627 HONG KONG HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 628 HONG KONG HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 629 HONG KONG ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 630 HONG KONG TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 631 HONG KONG FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 632 HONG KONG PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 633 HONG KONG MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 634 HONG KONG MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 635 HONG KONG PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 636 HONG KONG HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 637 HONG KONG GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 638 HONG KONG GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 639 HONG KONG IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 640 HONG KONG ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 641 HONG KONG OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 642 HONG KONG ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 643 HONG KONG PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 644 HONG KONG SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 645 HONG KONG H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 646 HONG KONG MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 647 HONG KONG ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 648 HONG KONG BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 649 HONG KONG BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 650 HONG KONG SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 651 HONG KONG INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 652 HONG KONG OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 653 HONG KONG INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 654 HONG KONG EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 655 HONG KONG REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 656 HONG KONG MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 657 HONG KONG GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 658 HONG KONG TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 659 HONG KONG CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 660 HONG KONG SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 661 HONG KONG TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 662 HONG KONG TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 663 HONG KONG TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 664 HONG KONG INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 665 HONG KONG TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 666 HONG KONG TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 667 USD THOUSAND

TABLE 668 TAIWAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 669 TAIWAN NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 670 TAIWAN PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 671 TAIWAN TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 672 TAIWAN HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 673 TAIWAN HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 674 TAIWAN ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 675 TAIWAN TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 676 TAIWAN FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 677 TAIWAN PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 678 TAIWAN MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 679 TAIWAN MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 680 TAIWAN PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 681 TAIWAN HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 682 TAIWAN GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 683 TAIWAN GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 684 TAIWAN IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 685 TAIWAN ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 686 TAIWAN OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 687 TAIWAN ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 688 TAIWAN PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 689 TAIWAN SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 690 TAIWAN H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 691 TAIWAN MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 692 TAIWAN ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 693 TAIWAN BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 694 TAIWAN BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 695 TAIWAN SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 696 TAIWAN INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 697 TAIWAN OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 698 TAIWAN INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 699 TAIWAN EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 700 TAIWAN REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 701 TAIWAN MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 702 TAIWAN GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 703 TAIWAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 704 TAIWAN CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 705 TAIWAN SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 706 TAIWAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 707 TAIWAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 708 TAIWAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 709 TAIWAN INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 710 TAIWAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 711 TAIWAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 712 USD THOUSAND

TABLE 713 REST OF ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 714 REST OF ASIA-PACIFIC NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 715 REST OF ASIA-PACIFIC PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 716 REST OF ASIA-PACIFIC TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 717 REST OF ASIA-PACIFIC HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 718 REST OF ASIA-PACIFIC HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 719 REST OF ASIA-PACIFIC ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 720 REST OF ASIA-PACIFIC TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 721 REST OF ASIA-PACIFIC FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 722 REST OF ASIA-PACIFIC PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 723 REST OF ASIA-PACIFIC MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 724 REST OF ASIA-PACIFIC MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 725 REST OF ASIA-PACIFIC PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 726 REST OF ASIA-PACIFIC HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 727 REST OF ASIA-PACIFIC GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 728 REST OF ASIA-PACIFIC GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 729 REST OF ASIA-PACIFIC IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 730 REST OF ASIA-PACIFIC ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 731 REST OF ASIA-PACIFIC OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 732 REST OF ASIA-PACIFIC ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 733 REST OF ASIA-PACIFIC PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 734 REST OF ASIA-PACIFIC SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 735 REST OF ASIA-PACIFIC H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 736 REST OF ASIA-PACIFIC MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 737 REST OF ASIA-PACIFIC ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 738 REST OF ASIA-PACIFIC BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 739 REST OF ASIA-PACIFIC BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 740 REST OF ASIA-PACIFIC SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 741 REST OF ASIA-PACIFIC INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 742 REST OF ASIA-PACIFIC OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 743 REST OF ASIA-PACIFIC INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 744 REST OF ASIA-PACIFIC EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 745 REST OF ASIA-PACIFIC REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 746 REST OF ASIA-PACIFIC MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 747 REST OF ASIA-PACIFIC GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 748 REST OF ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 749 REST OF ASIA-PACIFIC CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 750 REST OF ASIA-PACIFIC SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 751 REST OF ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 752 REST OF ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 753 REST OF ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 754 REST OF ASIA-PACIFIC INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 755 REST OF ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 756 REST OF ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

List of Figure

FIGURE 1 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: SEGMENTATION

FIGURE 2 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: MULTIVARIVATE MODELING

FIGURE 10 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: PRODUCT TYPE TIMELINE CURVE

FIGURE 11 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: APPLICATION COVERAGE GRID

FIGURE 12 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: SEGMENTATION

FIGURE 13 FOUR SEGMENTS COMPRISE THE ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY (2025)

FIGURE 14 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: EXECUTIVE SUMMARY

FIGURE 15 RISING SBS-IF PATIENT POPULATION IS EXPECTED TO DRIVE THE ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET DURING THE FORECAST PERIOD OF 2026 TO 2033.

FIGURE 16 NUTRITIONAL SUPPORT THERAPY IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET IN 2026 & 2033

FIGURE 17 STRATEGIC DECISIONS

FIGURE 18 PESTEL ANALYSIS

FIGURE 19 DROC ANALYSIS

FIGURE 20 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY TREATMENT MODALITY, 2025

FIGURE 21 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY MARKET ATTRIBUTION, 2025

FIGURE 22 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY DISEASE MANAGEMENT PHASE, 2025

FIGURE 23 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY PATIENT TYPE, 2025

FIGURE 24 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2025

FIGURE 25 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY END USER, 2025

FIGURE 26 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025

FIGURE 27 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: SNAPSHOT (2025)

FIGURE 28 ASIA-PACIFIC ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: COMPANY SHARE 2025 (%)

View Detailed Information

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

What is the expected growth rate of the Asia-Pacific type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market?

The market is expected to grow at a CAGR of 8.0% during 2026 to 2033, driven by increasing awareness of short bowel syndrome with intestinal failure (SBS-IF), rising demand for advanced nutritional and biologic therapies, improving diagnosis rates, and expanding healthcare investments across the region.

Which country dominates the Asia-Pacific type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market?

Japan dominated the market with a 23.14% share in 2025, supported by its advanced healthcare infrastructure, strong reimbursement policies, high adoption of specialized therapies, and increasing focus on rare gastrointestinal disease management.

Which country is the fastest growing in the Asia-Pacific type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market?

Japan is expected to be the fastest-growing region, recording a CAGR of 9.0% from 2026 to 2033, driven by increasing awareness and early diagnosis of SBS-IF, rising adoption of advanced nutritional therapies, growing investments in rare disease treatment, and continuous advancements in healthcare technologies.

What are the key growth drivers of the Asia-Pacific type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market?

A major growth driver is the rising awareness and improved diagnosis of SBS-IF, which is leading to earlier and more accurate detection of patients requiring long-term nutritional support and specialized therapies. At the same time, the increasing availability and adoption of advanced parenteral nutrition solutions and biologic treatments are significantly improving patient outcomes and expanding treatment uptake.

Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Size, Share, And Trends Analysis Report – Industry Overview and Forecast to 2033

Asia Pacific Type 1 Sbs If Short Bowel Syndrome With Intestinal Failure Treatment Market

CAGR : 8.00 %

Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Overview

Report Scope and Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Segmentation

Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Trends

Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome With Intestinal Failure) Treatment Market Dynamics

Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Scope

Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Regional Analysis

Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Share

Latest Developments in Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome With Intestinal Failure) Treatment Market

Get online access to the report on the World's First Market Intelligence Cloud

Table of Content

List of Table

List of Figure

Research Methodology

Customization Available

Frequently Asked Questions

What is the expected growth rate of the Asia-Pacific type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market?

Which country dominates the Asia-Pacific type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market?

Which country is the fastest growing in the Asia-Pacific type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market?

What are the key growth drivers of the Asia-Pacific type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market?

Industry Related Reports

Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Size, Share, And Trends Analysis Report – Industry Overview and Forecast to 2033

Asia Pacific Type 1 Sbs If Short Bowel Syndrome With Intestinal Failure Treatment Market

CAGR : 8.00 %

Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Overview

Report Scope and Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Segmentation

Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Trends

Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome With Intestinal Failure) Treatment Market Dynamics

Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Scope

Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Regional Analysis

Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Share

Latest Developments in Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome With Intestinal Failure) Treatment Market

Get online access to the report on the World's First Market Intelligence Cloud

Table of Content

List of Table

List of Figure

Research Methodology

Customization Available

Frequently Asked Questions

What is the expected growth rate of the Asia-Pacific type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market?

Which country dominates the Asia-Pacific type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market?

Which country is the fastest growing in the Asia-Pacific type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market?

What are the key growth drivers of the Asia-Pacific type 1 SBS-IF (short bowel syndrome with intestinal failure) treatment market?

Industry Related Reports

Browse Related Pages